

## Pharmacy Prior Authorization Form

Fax completed form to: 877.974.4411 toll free, or 616.942.8206

This form applies to: ☒ **Commercial (Traditional)** ☒ **Commercial (Individual/Optimized)**

☐ **Medicaid**

This request is: ☐ **Urgent** (life threatening) ☐ **Non-Urgent** (standard review)

Urgent means the standard review time may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.

## Penicillamine/Depen Titratabs®

### Member

Last Name: \_\_\_\_\_

First Name: \_\_\_\_\_

ID #: \_\_\_\_\_

DOB: \_\_\_\_\_ Gender: \_\_\_\_\_

Primary Care Physician: \_\_\_\_\_

Requesting Provider: \_\_\_\_\_

Prov. Phone: \_\_\_\_\_ Prov. Fax: \_\_\_\_\_

Provider Address: \_\_\_\_\_

Provider NPI: \_\_\_\_\_

Contact Name: \_\_\_\_\_

Provider Signature: \_\_\_\_\_

Date: \_\_\_\_\_

### Product Information

☐ New request ☐ Continuation request

Drug product: ☐ Depen Titratab 250 mg tablet  
☐ penicillamine 250 mg tablet

**Start date** (or date of next dose): \_\_\_\_\_

**Date of last dose** (if applicable): \_\_\_\_\_

**Dosing frequency:** \_\_\_\_\_

### Precertification Requirements

**Before this drug is covered, the patient must meet all of the following requirements:**

1. Diagnosis of Wilson's disease (hepatolenticular degeneration).
2. Diagnosis of cystinuria and treatment with conservative measures (e.g. high fluid intake, sodium and protein restriction, urinary alkalization) were ineffective, not tolerated, or contraindicated. *\*We require clinical documentation showing the patient's trial and compliance with conservative measures faxed to Priority Health\**

**Note:** Authorization for indications, dosing, or a route of administration not approved by the Food and Drug Administration (FDA) or recognized in CMS-accepted compendia (e.g. DrugDex, AHFS, U.S. Pharmacopeia, and also Clinical Pharmacology for oncology indications only) require supporting evidence for coverage. Please provide two published peer-reviewed literature articles supporting the appropriateness of the drug, the dosing of the drug, or the route of administration to be used for the identified indication.

---

**Priority Health Precertification Documentation**

**A. What condition is this drug being requested for?**

☐ Wilson's disease

☐ Cystinuria

☐ Other – the patient's condition is: \_\_\_\_\_

Rationale for use: \_\_\_\_\_

**B. Has the patient been treated with conservative measures?**

☐ Yes, please list what has been tried: \_\_\_\_\_

☐ No, rationale: \_\_\_\_\_

**C. What was the patients urine output on the most recent urinalysis?** \_\_\_\_\_

---

**Additional information**

**Note:** Quantity limit of 120 tablets per 30 days. For approval over the quantity limit, documentation proving conservative measures have continued in combination with Depen Titratabs or penicillamine 250 mg oral tablet, and that member has been compliant with these measures must be faxed to Priority Health.